J 2020

Targeting defective sphingosine kinase 1 in Niemann?Pick type C disease with an activator mitigates cholesterol accumulation

NEWTON, J., E. N. D. PALLADINO, C. WEIGEL, M. MACEYKA, M. H. GRALER et. al.

Základní údaje

Originální název

Targeting defective sphingosine kinase 1 in Niemann?Pick type C disease with an activator mitigates cholesterol accumulation

Autoři

NEWTON, J., E. N. D. PALLADINO, C. WEIGEL, M. MACEYKA, M. H. GRALER, C. E. SENKAL, R. D. ENRIZ, Pavlína MARVANOVÁ (203 Česká republika, domácí), J. JAMPILEK, S. LIMA, S. MILSTIEN a S. SPIEGEL

Vydání

Journal of Biological Chemistry, Bethesda, USA, Amer. Soc. Biochem. Mol. Biol. 2020, 0021-9258

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.157

Kód RIV

RIV/00216224:14160/20:00118106

Organizační jednotka

Farmaceutická fakulta

UT WoS

000550698000020

Klíčová slova anglicky

sphingosine kinase; cholesterol; Niemann?Pick type C; sphingolipids; lysosomal storage disease; genetic disorder; lipid metabolism; neurodegeneration; sphingolipid; sphingosine kinase (SphK); sphingosine-1-phosphate (S1P); NPC1

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 24. 2. 2021 08:25, Mgr. Hana Hurtová

Anotace

V originále

Niemann?Pick type C (NPC) disease is a lysosomal storage disorder arising from mutations in the cholesterol-trafficking protein NPC1 (95%) or NPC2 (5%). These mutations result in accumulation of low-density lipoprotein-derived cholesterol in late endosomes/lysosomes, disruption of endocytic trafficking, and stalled autophagic flux. Additionally, NPC disease results in sphingolipid accumulation, yet it is unique among the sphingolipidoses because of the absence of mutations in the enzymes responsible for sphingolipid degradation. In this work, we examined the cause for sphingosine and sphingolipid accumulation in multiple cellular models of NPC disease and observed that the activity of sphingosine kinase 1 (SphK1), one of the two isoenzymes that phosphorylate sphingoid bases, was markedly reduced in both NPC1 mutant and NPC1 knockout cells. Conversely, SphK1 inhibition with the isotype-specific inhibitor SK1-I in WT cells induced accumulation of cholesterol and reduced cholesterol esterification. Of note, a novel SphK1 activator (SK1-A) that we have characterized decreased sphingoid base and complex sphingolipid accumulation and ameliorated autophagic defects in both NPC1 mutant and NPC1 knockout cells. Remarkably, in these cells, SK1-A also reduced cholesterol accumulation and increased cholesterol ester formation. Our results indicate that a SphK1 activator rescues aberrant cholesterol and sphingolipid storage and trafficking in NPC1 mutant cells. These observations highlight a previously unknown link between SphK1 activity, NPC1, and cholesterol trafficking and metabolism.